Press Releases

 
Press Releases
  Date Title View
Nov 3, 2009
Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will participate on the Healthcare Private Company Panel at the Merriman Curhan Ford 6th Annual Investor Summit on Tuesday, November 10, 2009 at 2:00 p.m. eastern time.  Th...
Oct 29, 2009
Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for his contributions to the pharmaceutical industry. The annual All Star awards honor pioneers and leaders across several business and techn...
Oct 20, 2009
Lexington, MA -- Concert Pharmaceuticals, Inc. today announced that it will be presenting at the 2009 Boston Biotech R&D Conference being held at Harvard Medical School in Boston, Massachusetts.  Roger Tung, Ph.D., President and Chief Executive Officer will present an overview of the Company on Tuesday, Oc...
Oct 13, 2009
Lexington, MA -- Concert Pharmaceuticals, Inc. today announced that it has been chosen by AlwaysOn as one of the OnDC Top 100 Winners.  Inclusion in the OnDC 100 signifies major developments in the creation of new business opportunities that contribute to the renewed and continued prosperity of our country. Co...
Sep 14, 2009
San Antonio, TX -- Concert Pharmaceuticals, Inc. announced today the presentation of Phase 1 data on  CTP-347, a deuterium modified analog of paroxetine for the treatment of hot flashes.  Concert presented the results during a poster session at the American College of Clinical Pharmacology’s 38th Annual Meeting.  This pr...
Sep 3, 2009
LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Thomas Weisel Partners 2009 Healthcare Conference on Thursday, September 10, 2009 at 10:55 a.m. Eastern Time.  The conference will be held September 9-11, 2009 at the Four Seasons ...
Jun 2, 2009
LEXINGTON, Mass and London -- Concert Pharmaceuticals and GlaxoSmithKline (NYSE: GSK) announced today that they will collaborate to develop and commercialize deuterium-containing medicines. The deal includes three of Concert’s research and development programs; namely, CTP-518, a protease inhibitor for the treatment of HIV expected to e...
Jun 1, 2009
LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today its participation in the private company forum at the 30th Annual Goldman Sachs Global Healthcare Conference on Monday, June 8, 2009 from 3:30 – 5:30 p.m. Eastern Time.  Roger Tung, Ph.D., President and Chief Executive Officer, and Nancy Stuart, ...
May 11, 2009
LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today that its first patents have been granted by the U.S. Patent and Trademark Office.  These patents relate to specific compounds derived from Concert’s deuterium chemistry platform.  U.S. Patents 7,514,068 and 7,528,131 specifically claim deuterium analogs of ri...
Mar 16, 2009
LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today positive Phase I clinical trial results of CTP-347, an investigational non-hormonal treatment for vasomotor symptoms (hot flashes). CTP-347, a novel deuterium-modified analog of paroxetine discovered at Concert, was well-tolerated at all doses. Paroxetine is a serotonin reup...
FirstPrevious
...
17
NextLast
= add release to Briefcase